Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery.
The role of blood tests in identifying patients at high risk for post-operative venous thromboembolism is undefined. The aim of this study was to evaluate the correlation between pre-operative plasma levels of soluble fibrin polymers (SFP), as determined by a recently developed enzyme-linked immunosorbent assay (ELISA) assay (TpP), and the incidence of deep vein thrombosis (DVT) after elective neurosurgery. Blood samples for SFP assay were withdrawn on the day before surgery from 157 consecutive patients undergoing elective neurosurgery for brain or spinal tumour. Patients were randomized to subcutaneous enoxaparin (40 mg once daily) or placebo given for at least 7 days. All patients wore compression stockings. DVT was assessed by bilateral venography, performed on day 8 +/- 1. Thirty-four patients (21.7%) were found to have a DVT, proximal in 11 (7%) and isolated distal in 23. Patients with and without DVT had a plasma pre-operative SFP levels of 6.2 +/- 4.6 and 1.9 +/- 1.5 mg/ml respectively (mean +/- SD) (P < 0.001). SFP levels in patients with proximal and isolated distal DVT were 7.6 +/- 5.1 and 5.5 +/- 4.4 microg/ml, respectively (P = 0.22). SFP cut-off levels categorized patients into three classes of DVT incidence. The incidence of DVT was 7.4% (6 of 81) for SFP levels < 2 microg/ml, 20.4% (11 of 54) for levels between 2 and 4.5 microg/ml, and 77.3% (17 of 22) for levels > 4.5 microg/ml (P= 0.001, Cochran-Mantel-Haenszel test). We conclude that pre-operative SFP levels correlate with post-operative DVT in elective neurosurgery patients. Further studies are required to define whether pre-operative SFP measurement could be useful in patient management.
Sonaglia
F
F
Istituto di Medicina Interna e Medecina Vascolare, Università di Perugia, Italy.
Agnelli
G
G
Baroni
M
M
Severi
P
P
Quintavalla
R
R
D'Angelo
S V
SV
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D001932:Brain Neoplasms / Q000150:complications / Q000601:surgery; D017558:Elective Surgical Procedures / Q000009:adverse effects*; D017984:Enoxaparin / Q000627:therapeutic use; D005260:Female; D005337:Fibrin / Q000009:adverse effects*; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000009:adverse effects*; D012307:Risk Factors; D012995:Solubility; D013125:Spinal Neoplasms / Q000150:complications / Q000601:surgery; D020246:Venous Thrombosis / Q000097:blood* / Q000188:drug therapy / Q000209:etiology*
D015415:Biomarkers; D017984:Enoxaparin; D005337:Fibrin